| Name | Foslinanib |
|---|---|
| Synonyms |
4(1H)-Quinolinone, 2-(3-fluorophenyl)-6-methoxy-5-(phosphonooxy)-
2-(3-Fluorophenyl)-6-methoxy-4-oxo-1,4-dihydro-5-quinolinyl dihydrogen phosphate Foslinanib |
| Description | Foslinanib (TRX-818) is an orally bioavailable agent with potential antineoplastic and anti-vasculogenic mimicry (VM) activities, induces cancer cell apoptosis and inhibits cancer cell proliferation; also prevents tumor cell VM by blocking the formation of vasculogenic-like tubular structures through an as of yet undetermined mechanism of action. Liver Cancer Phase 2 Clinical |
|---|---|
| References | References View Related Products by Target Other Targets Liver Cancer |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 624.9±65.0 °C at 760 mmHg |
| Molecular Formula | C16H13FNO6P |
| Molecular Weight | 365.250 |
| Flash Point | 331.7±34.3 °C |
| Exact Mass | 365.046448 |
| LogP | 2.73 |
| Vapour Pressure | 0.0±1.9 mmHg at 25°C |
| Index of Refraction | 1.626 |